Is it safe to use TNF-α blockers for systemic inflammatory disease in patients with heart failure? Importance of dosage and receptor specificity

被引：13
作者：
Diamantopoulos, Andreas P. [1 ,2 ]
Larsen, Alf I. [3 ,4 ]
Omdal, Roald [5 ]
机构：
[1] Hosp Southern Norway, Dept Rheumatol, Kristiansand, Norway
[2] Norwegian Univ Sci & Technol NTNU, Fac Med, Trondheim, Norway
[3] Stavanger Univ Hosp, Dept Cardiol, Stavanger, Norway
[4] Univ Bergen, Inst Med, Bergen, Norway
[5] Stavanger Univ Hosp, Dept Internal Med, Clin Immunol Unit, Stavanger, Norway
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2013年 / 167卷 / 05期
关键词：
Heart failure; Cytokines; Tumor necrosis factor; Inflammatory diseases; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; CARDIOVASCULAR-DISEASE; DOUBLE-BLIND; INFLIXIMAB; THERAPY; DYSFUNCTION; APOPTOSIS; ETANERCEPT; PROMOTE;
D O I：
10.1016/j.ijcard.2012.11.112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Tumor necrosis factor-alpha (TNF-alpha) blockers are widely used in the treatment of chronic inflammatory diseases, especially chronic arthritis. Current guidelines advise against the use of such agents in patients who have a concomitant heart failure. Consequently, a group of patients with a devastating inflammatory disease cannot benefit from an excellent treatment option. After a critical review of the current literature, we conclude that there is not sufficient evidence to warn against such a regimen if recommended standard doses are used. A negative effect on the heart function seems to occur if unconventional high doses of TNF-alpha blockers are given. The theoretical background for this is discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：1719 / 1723
页数：5
相关论文
共 59 条
[1]   Signalling pathways of the TNF superfamily: A double-edged sword [J].
Aggarwal, BB .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756
[2]   Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure [J].
Bozkurt, B ;
Torre-Amione, G ;
Warren, MS ;
Whitmore, J ;
Soran, OZ ;
Feldman, AM ;
Mann, DL .
CIRCULATION, 2001, 103 (08) :1044-1047
[3]   Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats [J].
Bozkurt, B ;
Kribbs, SB ;
Clubb, FJ ;
Michael, LH ;
Didenko, VV ;
Hornsby, PJ ;
Seta, Y ;
Oral, H ;
Spinale, FG ;
Mann, DL .
CIRCULATION, 1998, 97 (14) :1382-1391
[4]  
Carter Angela M, 2005, Diab Vasc Dis Res, V2, P113, DOI 10.3132/dvdr.2005.018
[5]   A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses [J].
Chan, FKM ;
Shisler, J ;
Bixby, JG ;
Felices, M ;
Zheng, LX ;
Appel, M ;
Orenstein, J ;
Moss, B ;
Lenardo, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (51) :51613-51621
[6]   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[7]   Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy [J].
Dahlqvist, SR ;
Engstrand, S ;
Berglin, E ;
Johnson, O .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 (02) :107-111
[8]   Safety and efficacy of a soluble P75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure [J].
Deswal, A ;
Bozkurt, B ;
Seta, Y ;
Parilti-Eiswirth, S ;
Hayes, FA ;
Blosch, C ;
Mann, DL .
CIRCULATION, 1999, 99 (25) :3224-3226
[9]  
Edrees AF, 2005, CLIN EXP RHEUMATOL, V23, P469
[10]   Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2 [J].
Fontaine, V ;
Mohand-Said, S ;
Hanoteau, N ;
Fuchs, L ;
Pfizenmaier, K ;
Eisel, U .
JOURNAL OF NEUROSCIENCE, 2002, 22 (07)
123456